Analysis: reading the registry against the release
The public trial registry gives a different perspective on the same pipeline. The Uppsala study is registered as NCT06239636, an early phase 1 trial with a lead sponsor listed as Per-Ola Carlsson rather than Sana, an enrolment count of 2, and a start date in March 2024. That is the source of the durability data the company has been presenting for more than a year. It is a genuine clinical signal for the hypoimmune approach, and it is also a very small one, from a study Sana does not control and whose primary outcome is safety measured by treatment-related adverse events.
The company’s own registered studies are the ones it has stepped back from. SC291 in B-cell malignancies, SC291 in B-cell mediated autoimmune disease and SC262 in non-Hodgkin lymphoma are all listed as active but not recruiting, consistent with the suspended allogeneic CAR T programmes referenced in the cost commentary. Neither SC451 nor SG293 appears in the registry under a Sana-sponsored record. On the company’s stated timetable both should start this year, which means the registry entries are the first observable confirmation a reader can check.
The financial position frames how much time that leaves. Cash of $160.5 million, non-GAAP operating burn of $69.3 million for the half and a stated runway into mid-2027 are internally consistent, but the 10-Q’s going-concern conclusion says the same numbers do not cover twelve months from the filing date on management’s own assessment. The gap between the press release’s runway language and the filing’s going-concern language is the single most important thing in this reporting package, and only one of the two documents contains it.
Two mechanical items would move the picture. Mayo’s option over a further 7.5 million shares at $3.33 lapsed or was exercised by August 31, 2026, and the outcome is a fact rather than a forecast. And the contingent consideration and success payment liabilities, at $150,825 thousand and $24,477 thousand, rise as milestone probabilities and the share price rise, so clinical progress will mechanically enlarge reported losses even as it improves the business. Nothing in these filings establishes that SC451 or SG293 has entered a clinical trial.
What the documents say
Sana Biotechnology, Inc. (Nasdaq: SANA) reported second-quarter results on August 10, 2026 showing a narrower loss, a larger cash balance and no product yet in a company-sponsored clinical trial. The Seattle cell therapy developer held cash, cash equivalents and marketable securities of $160.5 million at June 30, 2026, against $138.4 million at December 31, 2025, and repeated its guidance of a cash runway into mid-2027.
The Form 10-Q filed the same day carries a disclosure the press release does not: management has determined that present capital resources may not be sufficient to fund planned operations for at least one year from the date of the report, and that there is substantial doubt as to the company’s ability to continue as a going concern.
The quarter
Research and development expenses were $30.7 million for the quarter and $59.4 million for the half, against $29.8 million and $67.0 million in the comparable periods of 2025. The quarterly increase of $0.9 million reflects higher research, laboratory and clinical development costs for the SC451 and SG293 programmes and higher third-party manufacturing costs, offset by lower personnel and facility costs. The half-year decrease of $7.6 million comes largely from costs incurred in the first half of 2025 for suspended allogeneic CAR T programmes that did not recur.
General and administrative expenses were $10.8 million for the quarter and $22.2 million for the half, against $10.3 million and $21.8 million. Non-cash stock-based compensation inside research and development fell to $3.2 million from $4.2 million in the quarter.
The largest single swing was not operational. Sana recognised non-cash expense of $23.9 million in the quarter and $32.3 million in the half from changes in the estimated fair value of success payment liabilities and contingent consideration, against $10.3 million and $12.2 million a year earlier. The company notes that those liabilities move with the probability of clinical and regulatory milestones and with its own market capitalisation and share price. The prior-year quarter also carried a $44.6 million non-cash impairment tied to the Bothell manufacturing facility and Seattle laboratory and office space, with no equivalent charge this year.
Net loss was $63.6 million, or $0.22 a share, against $93.8 million, or $0.39 a share. For the half the loss was $110.8 million, or $0.39 a share, against $143.2 million. On the company’s non-GAAP basis, which strips the revaluation and impairment items, the quarterly loss was $39.7 million against $38.9 million a year earlier, and operating cash burn for the half was $69.3 million against $79.0 million.
On the balance sheet, total assets were $431,522 thousand and total liabilities $276,954 thousand, of which contingent consideration accounted for $150,825 thousand and success payment liabilities $24,477 thousand, both up from $123,718 thousand and $19,238 thousand at the end of 2025. Stockholders’ equity fell to $154,568 thousand from $160,884 thousand. Accumulated deficit stands at $2.0 billion.
Where the money came from
Sana raised net proceeds of $93.3 million during the quarter from at-the-market share sales and an equity investment by Mayo Clinic. The Mayo transaction, entered in April 2026, sold 7.5 million shares at $3.33 for gross proceeds of about $25.0 million, with an option for Mayo to buy a further 7.5 million shares at the same price on or before August 31, 2026. As of the filing date Mayo had not exercised that option. Of the initial proceeds, about $21.3 million was allocated to common stock and additional paid-in capital and about $3.7 million to the option itself.
The share purchase came with a collaboration and licence agreement dated April 10, 2026, under which Sana took a non-exclusive licence to Mayo know-how relating to SC451 and islet cell therapy technologies and agreed to pay royalties on net sales of covered products. The proceeds are earmarked for the development of those products.
What is actually in the clinic
Sana’s headline clinical result comes from a study it does not sponsor. UP421, a primary human islet cell therapy modified with the company’s hypoimmune technology, was transplanted without immunosuppression into a patient with type 1 diabetes at Uppsala University Hospital under Dr Per-Ola Carlsson. The company reported survival and function of transplanted beta cells at 14 months, measured by circulating C-peptide, with levels rising on mixed meal tolerance testing and PET-MRI at week 12 and week 52 showing islet cells at the forearm transplant site. No safety issues were identified. The New England Journal of Medicine published a peer-reviewed letter on the 14-month results, and further data are due at the European Association for the Study of Diabetes annual meeting on October 2.
For its own candidates, Sana said it is completing GLP toxicology work and technology transfer for SC451, an iPSC-derived islet cell therapy, and expects to file an investigational new drug application and start a Phase 1/2 trial as early as this year. SG293, a CD8-targeted fusosome delivering CD19-directed CAR T genetic material, is expected to generate first-in-human data in non-Hodgkin lymphoma as early as this year. SG227, the BCMA-directed equivalent for multiple myeloma, is targeted to enter the clinic as early as mid-2027, contingent on SG293’s early profile.
